Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Andrea, Vaclavkova"'
Publikováno v:
Clinical Pharmacology & Therapeutics. 113:692-703
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e83f2ababfbf794f49a7df78d6a18a4f
https://doi.org/10.1002/cpt.2827
https://doi.org/10.1002/cpt.2827
Autor:
Mark S, Freedman, Carlo, Pozzilli, Eva Kubala, Havrdova, Alexandre, Lemle, Michel, Burcklen, Anna, Larbalestier, Brian, Hennessy, Tatiana, Sidorenko, Andrea, Vaclavkova, Tomas, Olsson
Publikováno v:
Neurology. 99:e762-e774
ObjectiveTo evaluate the dose-response relationship of 10, 20, and 40 mg ponesimod and long-term efficacy and safety of ponesimod 20 mg using an analysis of combined data from the phase 2 Core and Extension studies in patients with relapsing-remittin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd4ac00dbb03653b5ac76c9cf9253087
https://doi.org/10.1212/wnl.0000000000200606
https://doi.org/10.1212/wnl.0000000000200606
Autor:
Jasper Dingemanse, Jim Bush, Matthias Hoch, Andrea Vaclavkova, Andreas Krause, Pierre-Eric Juif
Publikováno v:
The Journal of Clinical Pharmacology. 57:401-410
Ponesimod, a potent selective sphingosine-1-phosphate receptor 1 modulator, leads to a reduction in circulating total lymphocyte count and transient decreases in heart rate (HR). Based on a modeling and simulation approach, this study was conducted t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d8407f3ab3dfa922434fff30c7a9aeb
https://doi.org/10.1002/jcph.820
https://doi.org/10.1002/jcph.820
Autor:
Darren Wilbraham, Daniela Baldoni, Maribel Reyes, Pierre-Eric Juif, Andrea Vaclavkova, Jasper Dingemanse, Matthias Hoch, Salvatore Febbraro
Publikováno v:
International Journal of Molecular Sciences, Vol 18, Iss 12, p 2636 (2017)
International Journal of Molecular Sciences; Volume 18; Issue 12; Pages: 2636
International Journal of Molecular Sciences; Volume 18; Issue 12; Pages: 2636
The pharmacokinetics, pharmacodynamics, tolerability, and food effect of cenerimod, a potent sphingosine-1-phosphate subtype 1 receptor modulator, were investigated in three sub-studies. Two double-blind, placebo-controlled, randomised studies in hea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0c4f4eb091bcb561bf0119f4cd4dd0f
https://www.mdpi.com/1422-0067/18/12/2636
https://www.mdpi.com/1422-0067/18/12/2636
Autor:
Pierre-Eric, Juif, Daniela, Baldoni, Maribel, Reyes, Darren, Wilbraham, Salvatore, Febbraro, Andrea, Vaclavkova, Matthias, Hoch, Jasper, Dingemanse
Publikováno v:
International Journal of Molecular Sciences
The pharmacokinetics, pharmacodynamics, tolerability, and food effect of cenerimod, a potent sphingosine-1-phosphate subtype 1 receptor modulator, were investigated in three sub-studies. Two double-blind, placebo-controlled, randomised studies in hea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3e32702bd0d13a8884dc2e7026d52965
https://pubmed.ncbi.nlm.nih.gov/29211013
https://pubmed.ncbi.nlm.nih.gov/29211013
Autor:
Andrea Vaclavkova, Paul-Gunther Sator, Péter Holló, Daniele D'Ambrosio, Sergio Chimenti, Petr Arenberger, Mylene Stefani, Michel Burcklen
Publikováno v:
The Lancet. 384:2036-2045
We assessed the efficacy, safety, and tolerability of ponesimod, an oral, selective, reversible modulator of sphingosine 1-phosphate receptor 1, in patients with moderate to severe chronic plaque psoriasis.Between Sept 22, 2010, and Oct 24, 2012, pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::121d38c67e2504ec6042cfae43bebbbf
https://doi.org/10.1016/s0140-6736(14)60803-5
https://doi.org/10.1016/s0140-6736(14)60803-5
Autor:
Andrea Vaclavkova, A. Strong, Jasper Dingemanse, J. Bush, Matthias Hoch, Pierre-Eric Juif, Andreas Krause
Publikováno v:
Clinical Therapeutics. 37:e36-e37
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::970352131a576136f2aa8948465e89d1
https://doi.org/10.1016/j.clinthera.2015.05.114
https://doi.org/10.1016/j.clinthera.2015.05.114
Publikováno v:
Clinical Therapeutics. 35(8):e68-e69
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af139a25430da8ef46b5cb1e373000f9
Autor:
Valenzuela, Belén, Poggesi, Italo, Luyckx, Nicolas, Vaclavkova, Andrea, Pérez‐Ruixo, Juan José
Publikováno v:
Clinical Pharmacology & Therapeutics; Mar2023, Vol. 113 Issue 3, p692-703, 12p
Autor:
Freedman, Mark S., Pozzilli, Carlo, Havrdova, Eva Kubala, Lemle, Alexandre, Burcklen, Michel, Larbalestier, Anna, Hennessy, Brian, Sidorenko, Tatiana, Vaclavkova, Andrea, Olsson, Tomas, onbehalf of Ponesimod Phase II Study Group, Ponesimod Phase II Study Group
Publikováno v:
Neurology; 8/23/2022, Vol. 99 Issue 8, pe762-e774, 13p